Bristol-Myers Squibb Receives Positive CHMP Opinion for Daklinza for Treatment of Chronic Hepatitis C in the European Union

By: via Benzinga
Bristol-Myers Squibb Company (NYSE: BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.